Clinical Trial Update: A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 study of TRS005 in CD20-positive relapsed/refractory diffuse large B-cell lymphoma. The trial is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• TRS005 (TRS005)

Snippet

Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Conditions: CD20-positive Diffuse Large B-Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING